A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
A phase 2 trial of Flumatinib and Imatinib in Leukaemia, run by Jiangsu HengRui Medicine Co., Ltd., with a status the registry has not verified recently.
Overview
A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia is a phase 2 interventional study registered as NCT01503502 by Jiangsu HengRui Medicine Co., Ltd., with 150 participants planned, started 2011-08 and due to reach its primary completion in 2012-06. Interventions recorded: flumatinib, imatinib. Conditions recorded: Myelogenous Leukemia, Chronic.
Linked to the drug Flumatinib because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialStudy of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL
Shares Flumatinib, Leukaemia (all types) and the tag pipeline.
- TrialStudy of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients
Shares Flumatinib, Leukaemia (all types) and the tag pipeline.
- TrialTreatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma
Shares Leukaemia (all types) and the tag pipeline.
- TrialEfficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)
Shares Leukaemia (all types) and the tag pipeline.
- TrialRasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
Shares Leukaemia (all types) and the tag pipeline.
- TrialA Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialHetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.